MiNK Therapeutics, Inc. cash flow to debt ratio of -114.40% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

MiNK Therapeutics, Inc.'s free cash flow has increased -37.99% from $-9.56M last year to $-5.93M, signaling increasing performance

MiNK Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

MiNK Therapeutics, Inc.'s debt has increased relative to shareholder equity from -0.25 last year to 0.00 today, signaling weakened financials

MiNK Therapeutics, Inc. has a net cash position, so leverage is healthy.

MiNK Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

MiNK Therapeutics, Inc. has insufficient data to evaluate this check.

MiNK Therapeutics, Inc.'s short-term assets of $13.85M exceed its short-term liabilities of $13.03M

MiNK Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

MiNK Therapeutics, Inc.'s return on equity of 76.02%, is higher than 15.00%, indicating good performance

MiNK Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

MiNK Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.

MiNK Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

MiNK Therapeutics, Inc. has negative free cash flow, indicating cash burn

MiNK Therapeutics, Inc.'s yearly earnings has decreased 15.85% since last year from $-10.78M to $-12.49M, signaling decreasing performance

MiNK Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -415.48% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

MiNK Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

MiNK Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

MiNK Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

MiNK Therapeutics, Inc. is undervalued relative to its fair value price of 2.29K based on Discounted Cash Flow model

MiNK Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

MiNK Therapeutics, Inc. is undervalued relative to its fair value price of 2.67K based on EBITDA multiple model

MiNK Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

MiNK Therapeutics, Inc. has insufficient data to evaluate this check.

MiNK Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

MiNK Therapeutics, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

MiNK Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue